



## Michael Knauer

### Kontakt

Michael Knauer

### Bereiche

Brustzentrum St.Gallen, Medizinische Onkologie und Hämatologie

## Publikationen (43)

Reimer T, Stachs A, Veselinovic K, Kühn T, Heil J, Polata S, Marme F, Müller T, Hildebrandt G, Krug D, Ataseven B, Reitsamer R, Ruth S, Denkert C, Bekes I, Zahm D, Thill M, Golatta M, Holtschmidt J, Knauer M, Nekjudova V, Loibl S, Gerber B. Axillary Surgery in Breast Cancer – Primary Results of the INSEMA Trial. *N Engl J Med* 2024

Weber W, Heidinger M, Hayoz S, Matrai Z, Tausch C, Henke G, Zwahlen D, Gruber G, Zimmermann F, Montagna G, Andreozzi M, Goldschmidt M, Schulz C, Müller A, Ackerknecht M, Tampaki E, Bjelic-Radisic V, Kurzeder C, Sávolt Á, Smanyakó V, Hagen D, Müller D, Gnant M, Loibl S, Fitzal F, Markellou P, Bekes I, Egle D, Heil J, Knauer M. ASO Visual Abstract: Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). *Ann Surg Oncol* 2023

Weber W, Heidinger M, Hayoz S, Matrai Z, Tausch C, Henke G, Zwahlen D, Gruber G, Zimmermann F, Montagna G, Andreozzi M, Goldschmidt M, Schulz C, Müller A, Ackerknecht M, Tampaki E, Bjelic-Radisic V, Kurzeder C, Sávolt Á, Smanyakó V, Hagen D, Müller D, Gnant M, Loibl S, Fitzal F, Markellou P, Bekes I, Egle D, Heil J, Knauer M. Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). *Ann Surg Oncol* 2023

Tausch C, Däster K, Hayoz S, Matrai Z, Fitzal F, Henke G, Zwahlen D, Gruber G, Zimmermann F, Andreozzi M, Goldschmidt M, Schulz C, Maggi N, Saccilotto R, Heidinger M, Müller A, Tampaki E, Bjelic-Radisic V, Sávolt Á, Smanyakó V, Hagen D, Müller D, Gnant M, Loibl S, Markellou P, Bekes I, Egle D, Ruhstaller T, Muenst S, Kümmel S, Vrieling C, Satler R, Becciolini C, Bucher S, Kurzeder C, Simonson C, Fehr P, Gabriel N, Maráz R, Sarlos D, Dedes K, Leo C, Berclaz G, Fansa H, Hager C, Reisenberger K, Singer C, Montagna G, Reitsamer R, Winkler J, Lam G, Fehr M, Naydina T, Kohlik M, Clerc K, Ostapenko V, Lelièvre L, Heil J, Knauer M, Weber W. Trends in use of neoadjuvant systemic therapy in patients with clinically node-positive breast cancer in Europe: prospective TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). *Breast Cancer Res Treat* 2023; 201:215-225.

Maranta A, Broder S, Fritzsche C, Knauer M, Thürlimann B, Jochum W, Ruhstaller T. Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer. *Breast* 2020; 51:120-126.

Henke G, Kurzeder C, Gyr A, Ballardini B, Matrai Z, Gnant M, Fitzal F, Hawle H, Ackerknecht M, Muenst S, Zwahlen D, Ruhstaller T, Gerard M, Hayoz S, Ribí K, Knauer M, Weber W. Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. *Trials* 2018; 19:667.

Rageth C, Morris E, Boos A, Sonnenschein M, Malhaire C, Knauer M, Dellas S, Foschini M, Fallenberg E, Baltzer P, Dammann F, Tausch C, Decker T, Munding A, Kubik-Huch R, Pinker K, O'Flynn E, Varga Z. Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions). *Breast Cancer Res Treat* 2018

Khaled H, Gamal H, Lotayef M, Knauer M, Thürliman B. The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017: Egyptian view. *Breast Cancer Res Treat* 2018

Galimberti V, Knauer M, Tondini C, Di Leo A, Colleoni M, Regan M, Coates A, Gelber R, Goldhirsch A, Littlejohn D, Taffurelli M, Cole B, Viale G, Veronesi P, Vicini E, Intra M, Mazzarol G, Massarut S, Zgajnar J, International Breast Cancer Study Group Trial 23-01. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial. *Lancet Oncol* 2018

Gnant M, Montagna G, Meani F, Mechera R, Landin J, Knauer M, Kappos E, Hauser N, Harder Y, Günthert A, Ganz-Blättler U, Fulco I, Fehr M, Ritter M, Saccolotto R, Schwab F, Sacchini V, Pusic A, El-Tamer M, Romics L, Wyld L, Tansley A, Kovacs T, Lohsiriwat V, Soysal S, Zeindler J, Tausch C, Steffens D, Farhadi J, Dubsy P, Heil J, Blohmer J, Paulinelli R, Urban C, Brenelli F, Biazus J, Fitzal F, Reitsamer R, Koller R, Bjelic-Radiscic V, Kurzeder C, Haug M, Hoffmann J, Matrai Z, Catanuto G, Bucher S, Svensjö T, de Boniface J, Rubio I, Gouveia P, Cardoso M, Olsha O, Allweis T, Hadar T, Barry M, Gentilini O, Galimberti V, Weber W. Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy. *Breast Cancer Res Treat* 2018

Weber W, Sarlos D, Leo C, Canonica C, Gabriel N, Zeindler J, Cassoly E, Andrieu C, Soysal S, Ruhstaller T, Fehr P, Knauer M, Pioch V, Güth U, Hess T, Tausch C, Hayoz S, Fehr M, Ribl K, Hawle H, Lupatsch J, Matter-Walstra K, Chiesa F, Dedes K, Berclaz G, Lelièvre L, Swiss Group for Clinical Cancer Research (SAKK). Impact of a Surgical Sealing Patch on Lymphatic Drainage After Axillary Dissection for Breast Cancer: The SAKK 23/13 Multicenter Randomized Phase III Trial. *Ann Surg Oncol* 2018; 25:2632-2640.

Fitzal F, Gnant M, Greil R, Soelkner L, Schrenk P, Bartsch R, Singer C, Balic M, Hubalek M, Steger G, Knauer M, Bjelic-Radiscic V, ABCSG. Impact of Breast Surgery in Primary Metastasized Breast Cancer: Outcomes of the Prospective Randomized Phase III ABCSG-28 POSYITIVE Trial. *Ann Surg* 2018

Bösch M, Knauer M, Ruhstaller T, Jochum W, Gastl G, Sopper S, Mörbe U, Novkovic M, Cheng H, Onder L, Ludewig B. Interleukin 7-expressing fibroblasts promote breast cancer growth through sustenance of tumor cell stemness. *Oncoimmunology* 2018; 7:e1414129.

Weber W, Reitsamer R, Koller R, Heil J, Hahn M, Blohmer J, Hoffmann J, Solbach C, Heitmann C, Gerber B, Haug M, Bjelic-Radiscic V, Dubsy P, Fitzal F, Soysal S, El-Tamer M, Sacchini V, Knauer M, Tausch C, Hauser N, Günthert A, Harder Y, Kappos E, Schwab F, Kurzeder C. First international consensus conference on standardization of oncoplastic breast conserving surgery. *Breast Cancer Res Treat* 2017; 165:139-149.

Gnant M, Kwasny W, Dubsy P, Selim U, Fitzal F, Hochreiner G, Wette V, Sevelde P, Ploner F, Bartsch R, Fesl C, Greil R, Steger G, Eiermann W, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radiscic V, Balic M, Eidtmann H, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. *Ann Oncol* 2014; 26:313-20.

Knauer M, Thürlimann B. Adjuvant bisphosphonates in breast cancer treatment. *Breast Care (Basel)* 2014; 9:319-22.

Knauer M. Sentinel Node Biopsy nach adjuvanter Chemotherapie bei N1-ycN0 - Können wir auf die Axilladisektion nach einem Downstaging der Lymphknoten verzichten?. *Leading Opinions Hämatologie / Onkologie* 2014:42-44.

Luketina R, Knauer M, Köhler G, Koch O, Strasser K, Egger M, Emmanuel K. Comparison of a standard CO2 pressure pneumoperitoneum insufflator versus AirSealTM: study protocol of a randomized controlled trial. *Trials* 2014; 15:239.

Knauer M, Filipits M, Dubsy P. Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?. *Breast Care (Basel)* 2014; 9:97-100.

Filipits M, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C, Ferree S, Liu S, Cowens J, Gnant M, Dubsy P, Mlineritsch B, Singer C, Nielsen T, Rudas M, Greil R, Stöger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, Müller-Holzner E, Austrian Breast and Colorectal Cancer Study Group. The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer. *Clin Cancer Res* 2014; 20:1298-305.

Gnant M, Steger G, Balic M, Ressler S, Cowens J, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen T, Bartsch R, Fitzal F, Dubsky P, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. *Ann Oncol* 2013; 25:339-45.

Retèl V, Joore M, Drukker C, Bueno-de-Mesquita J, Knauer M, van Tinteren H, Linn S, van Harten W. Prospective cost-effectiveness analysis of genomic profiling in breast cancer. *Eur J Cancer* 2013; 49:3773-9.

Drukker C, van de Vijver M, Rutgers E, Sonke G, van 't Veer L, Knauer M, Roumen R, Wesseling J, van Tinteren H, van Harten W, Retèl V, Bueno-de-Mesquita J, Linn S. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study. *Int J Cancer* 2013; 133:929-36.

Langsteger W, Haim S, Knauer M, Waldenberger P, Emmanuel K, Loidl W, Wolf I, Beheshti M. Imaging of bone metastases in prostate cancer: an update. *Q J Nucl Med Mol Imaging* 2012; 56:447-58.

Knauer M, Gnant M, Fitzal F. Results of the First Austrian Multidisciplinary Expert Panel on Controversies in Local Treatment of Breast Cancer. *Breast Care (Basel)* 2012; 7:61-66.

Berghoff A, Preusser M, Steger G, Zielinski C, Gnant M, Mader R, Dieckmann K, Fitzal F, Eiter H, Knauer M, Rottenfusser A, Rudas M, Pluschnig U, Dubsky P, De Vries C, Bago-Horvath Z, Bartsch R. Brain metastases free survival differs between breast cancer subtypes. *Br J Cancer* 2012; 106:440-6.

Esserman L, van Leeuwen F, Linn S, Moore D, Glas A, Mook S, Retèl V, Knauer M, Rutgers E, Shieh Y, van 't Veer L. Impact of mammographic screening on the detection of good and poor prognosis breast cancers. *Breast Cancer Res Treat* 2011; 130:725-34.

Knauer M, Cardoso F, Wesseling J, Bedard P, Linn S, Rutgers E, van 't Veer L. Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature. *Br J Cancer* 2010; 103:1788-93.

Retèl V, Joore M, Knauer M, Linn S, Hauptmann M, Harten W. Cost-effectiveness of the 70-gene signature versus St. Gallen guidelines and Adjuvant Online for early breast cancer. *Eur J Cancer* 2010; 46:1382-91.

Knauer M, Linn S, Bueno-de-Mesquita J, Koornstra R, van de Vijver M, Hauptmann M, Bender R, Rutgers E, Mook S, van 't Veer L. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. *Breast Cancer Res Treat* 2010; 120:655-61.

Mook S, Knauer M, Bueno-de-Mesquita J, Retèl V, Wesseling J, Linn S, Van't Veer L, Rutgers E. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. *Ann Surg Oncol* 2010; 17:1406-13.

Winder T, de Vries A, Wenzl E, Drexel H, Knauer M, Hartmann B, Dirschmid K, Rhomberg S, Mündlein A, Lang A. Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer. *Oncol Rep* 2009; 21:1283-7.

Knauer M. Gene expression profiling in breast cancer – design of a pooled database to address open questions. *Eur Surg* 2009; 41:221-227.

Knauer M, Wenzl E, Offner F, Säly C, Jasarevic Z, Alton R, Winder T, Lang A, Köberle-Wührer R, Schneider Y, Haid A, deVries A. Adjuvant extension of chemotherapy after neoadjuvant therapy may not improve outcome in early-stage breast cancer. *Eur J Surg Oncol* 2008; 35:798-804.

Knauer M, Haid A, Ammann K, Lang A, Offner F, Türtscher M, Cerkl P, Wenzl E. Complications after oesophagectomy with possible contribution of neoadjuvant therapy including an EGFR-antibody to a fatal outcome. *World J Surg Oncol* 2007; 5:114.

Knauer M, Devries A, Wenzl E, Haid A. Standardization of pathologic complete response rates in breast cancer treatment. *Breast Cancer Res Treat* 2007; 110:395-6.

Haid A, Wenzl E, Haid B, Toepfker M, Schuster A, Köberle-Wührer R, Jasarevic Z, Dunzinger S, Knauer M, Offner F. Intra-operative sonography: a valuable aid during breast-conserving surgery for occult breast cancer. *Ann Surg Oncol* 2007; 14:3090-101.

Knauer M, Konstantiniuk P, Haid A, Wenzl E, Riegler-Keil M, Pöstlberger S, Reitsamer R, Schrenk P. Multicentric breast cancer: a new indication for sentinel node biopsy--a multi-institutional validation study. *J Clin Oncol* 2006; 24:3374-80.

Haid A, Knauer M, Köberle-Wührer R, Ammann K, Koller L, Eiter H, Lang A, Wenzl E. Medium-term follow-up data after sentinel node biopsy alone for breast cancer. *Eur J Surg Oncol* 2006; 32:1180-5.

Knauer M, Haid A, Gruber-Mösenbacher U, Wenzl E. [Mesenteric inflammatory veno-occlusive disease (MIVOD)--a rare cause of intestinal ischemia]. *Wien Klin Wochenschr* 2005; 117:610-4.

Haid A, Knauer M, Köberle-Wührer R, Wenzl E. [Sentinel node biopsy in breast cancer: techniques and indications]. *Wien Klin Wochenschr* 2005; 117:121-8.

Haid A, Kuehn T, Konstantiniuk P, Köberle-Wührer R, Knauer M, Kreienberg R, Zimmermann G. Shoulder-arm morbidity following axillary dissection and sentinel node only biopsy for breast cancer. *Eur J Surg Oncol* 2002; 28:705-10.

Haid A, Sturn H, Hergan K, Ammann M, Jasarevic Z, Peschina W, Fritzsche H, Burtscher J, Knauer M, Köberle-Wührer R, Zimmermann G. Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: a comparative evaluation. *Breast Cancer Res Treat* 2002; 73:31-6.

## Projekte (1)

**SAKK 23/13 Impact of a Surgical Sealing Patch on Lymphatic Drainage after Axillary Lymph Node Dissection for Breast Cancer. A Multicenter Randomized Phase III Trial**

*Klinische Forschung - 12.03.2015 - 27.08.2017*

*Automatisch geschlossen*

---

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

[support.forschung@kssg.ch](mailto:support.forschung@kssg.ch)